Savara Inc (SVRA)
4.56
+0.13
(+2.93%)
USD |
NASDAQ |
Jul 08, 10:25
Savara Research and Development Expense (TTM): 52.33M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 52.33M |
| December 31, 2023 | 44.26M |
| September 30, 2023 | 39.14M |
| June 30, 2023 | 33.43M |
| March 31, 2023 | 30.93M |
| December 31, 2022 | 27.88M |
| September 30, 2022 | 27.87M |
| June 30, 2022 | 26.25M |
| March 31, 2022 | 27.09M |
| December 31, 2021 | 28.99M |
| September 30, 2021 | 31.53M |
| June 30, 2021 | 30.60M |
| March 31, 2021 | 29.43M |
| December 31, 2020 | 35.04M |
| September 30, 2020 | 33.60M |
| June 30, 2020 | 37.58M |
| March 31, 2020 | 41.96M |
| December 31, 2019 | 38.78M |
| September 30, 2019 | 39.92M |
| June 30, 2019 | 39.85M |
| March 31, 2019 | 38.65M |
| December 31, 2018 | 37.17M |
| September 30, 2018 | 33.75M |
| June 30, 2018 | 29.21M |
| March 31, 2018 | 24.10M |
| Date | Value |
|---|---|
| December 31, 2017 | 18.51M |
| September 30, 2017 | 15.57M |
| June 30, 2017 | 12.74M |
| March 31, 2017 | 9.868M |
| December 31, 2016 | 14.80M |
| September 30, 2016 | -5.478M |
| June 30, 2016 | -0.29M |
| March 31, 2016 | 6.154M |
| December 31, 2015 | 4.321M |
| September 30, 2015 | 26.04M |
| June 30, 2015 | 24.11M |
| March 31, 2015 | 21.20M |
| December 31, 2014 | 19.44M |
| September 30, 2014 | 18.02M |
| June 30, 2014 | 15.72M |
| March 31, 2014 | 13.74M |
| December 31, 2013 | 12.90M |
| September 30, 2013 | 11.49M |
| June 30, 2013 | 10.05M |
| March 31, 2013 | 9.321M |
| December 31, 2012 | 8.088M |
| September 30, 2012 | 7.730M |
| June 30, 2012 | 8.123M |
| March 31, 2012 | 7.358M |
| December 31, 2011 | 5.758M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
26.25M
Minimum
Jun 2022
52.33M
Maximum
Mar 2024
34.56M
Average
33.43M
Median
Jun 2023
Research and Development Expense (TTM) Benchmarks
| Madrigal Pharmaceuticals Inc | 281.43M |
| Aldeyra Therapeutics Inc | 24.41M |
| Akero Therapeutics Inc | 170.66M |
| 89bio Inc | 147.35M |
| Vigil Neuroscience Inc | 61.43M |